How much revenue did AC Immune generate this year?
AC Immune has achieved a revenue of 30.5 M CHF this year.
AC Immune Revenue 2024
AC Immune Revenue
30.5 M CHF
Ticker
ACIU
ISIN
CH0329023102
WKN
A2AR5F
In 2024, AC Immune's sales reached 30.5 M CHF, a 106.05% difference from the 14.8 M CHF sales recorded in the previous year.
The AC Immune Revenue history
| YEAR | REVENUE (undefined CHF) | GROSS MARGIN (%) |
|---|---|---|
| 2030e | 417.11 | - |
| 2029e | 353.29 | - |
| 2028e | 110.41 | - |
| 2027e | 81.43 | - |
| 2026e | 67.54 | - |
| 2025e | 120.56 | - |
| 2024e | 30.5 | - |
| 2023 | 14.8 | - |
| 2022 | 3.9 | - |
| 2021 | - | - |
| 2020 | 15.4 | - |
| 2019 | 110.5 | - |
| 2018 | 7.2 | - |
| 2017 | 20.3 | - |
| 2016 | 23.2 | - |
| 2015 | 39.1 | - |
| 2014 | 30.3 | - |
| 2013 | 8.6 | - |
AC Immune Revenue, EBIT, Net Income CH0329023102 · A2AR5F
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into AC Immune, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AC Immune from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AC Immune’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of AC Immune. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into AC Immune’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing AC Immune’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AC Immune’s growth potential.
AC Immune Revenue, EBIT and net profit per share
| Date | AC Immune Revenue | AC Immune EBIT | AC Immune Net Income |
|---|---|---|---|
| 2030e | 417.11 M CHF | 270.86 M CHF | 235.2 M CHF |
| 2029e | 353.29 M CHF | 259.97 M CHF | 165.59 M CHF |
| 2028e | 110.41 M CHF | -2.01 M CHF | 24.4 M CHF |
| 2027e | 81.43 M CHF | -22.93 M CHF | 7 M CHF |
| 2026e | 67.54 M CHF | -29.85 M CHF | -39.41 M CHF |
| 2025e | 120.56 M CHF | -1.15 M CHF | -10.15 M CHF |
| 2024e | 30.5 M CHF | -37.67 M CHF | -41.67 M CHF |
| 2023 | 14.8 M CHF | -53.62 M CHF | -54.23 M CHF |
| 2022 | 3.9 M CHF | -70.8 M CHF | -70.8 M CHF |
| 2021 | 0 CHF | -79 M CHF | -73 M CHF |
| 2020 | 15.4 M CHF | -61.3 M CHF | -61.9 M CHF |
| 2019 | 110.5 M CHF | 44.5 M CHF | 45.4 M CHF |
| 2018 | 7.2 M CHF | -49.6 M CHF | -51 M CHF |
| 2017 | 20.3 M CHF | -22.5 M CHF | -26.4 M CHF |
| 2016 | 23.2 M CHF | -10.5 M CHF | -7.1 M CHF |
| 2015 | 39.1 M CHF | 18.6 M CHF | 20.3 M CHF |
| 2014 | 30.3 M CHF | 10.7 M CHF | 10.7 M CHF |
| 2013 | 8.6 M CHF | -11.5 M CHF | -11.2 M CHF |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2013 | 8.6 M CHF | -11.5 M CHF | -11.2 M CHF |
| 2014 | 30.3 M CHF | 10.7 M CHF | 10.7 M CHF |
| 2015 | 39.1 M CHF | 18.6 M CHF | 20.3 M CHF |
| 2016 | 23.2 M CHF | -10.5 M CHF | -7.1 M CHF |
| 2017 | 20.3 M CHF | -22.5 M CHF | -26.4 M CHF |
| 2018 | 7.2 M CHF | -49.6 M CHF | -51 M CHF |
| 2019 | 110.5 M CHF | 44.5 M CHF | 45.4 M CHF |
| 2020 | 15.4 M CHF | -61.3 M CHF | -61.9 M CHF |
| 2021 | 0 CHF | -79 M CHF | -73 M CHF |
| 2022 | 3.9 M CHF | -70.8 M CHF | -70.8 M CHF |
| 2023 | 14.8 M CHF | -53.62 M CHF | -54.23 M CHF |
| 2024e | 30.5 M CHF | -37.67 M CHF | -41.67 M CHF |
| 2025e | 120.56 M CHF | -1.15 M CHF | -10.15 M CHF |
| 2026e | 67.54 M CHF | -29.85 M CHF | -39.41 M CHF |
| 2027e | 81.43 M CHF | -22.93 M CHF | 7 M CHF |
| 2028e | 110.41 M CHF | -2.01 M CHF | 24.4 M CHF |
| 2029e | 353.29 M CHF | 259.97 M CHF | 165.59 M CHF |
| 2030e | 417.11 M CHF | 270.86 M CHF | 235.2 M CHF |
AC Immune stock margins CH0329023102 · A2AR5F
The AC Immune margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AC Immune. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AC Immune.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the AC Immune's sales revenue. A higher gross margin percentage indicates that the AC Immune retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the AC Immune's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the AC Immune's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AC Immune's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AC Immune. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AC Immune's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
AC Immune Margin History
| AC Immune Gross margin | AC Immune Profit margin | AC Immune EBIT margin | AC Immune Profit margin |
|---|---|---|---|
| 2030e | 0 % | 64.94 % | 56.39 % |
| 2029e | 0 % | 73.59 % | 46.87 % |
| 2028e | 0 % | -1.82 % | 22.1 % |
| 2027e | 0 % | -28.16 % | 8.6 % |
| 2026e | 0 % | -44.19 % | -58.35 % |
| 2025e | 0 % | -0.96 % | -8.42 % |
| 2024e | 0 % | -123.53 % | -136.63 % |
| 2023 | 0 % | -362.3 % | -366.41 % |
| 2022 | 0 % | -1,815.38 % | -1,815.38 % |
| 2021 | 0 % | 0 % | 0 % |
| 2020 | 0 % | -398.05 % | -401.95 % |
| 2019 | 0 % | 40.27 % | 41.09 % |
| 2018 | 0 % | -688.89 % | -708.33 % |
| 2017 | 0 % | -110.84 % | -130.05 % |
| 2016 | 0 % | -45.26 % | -30.6 % |
| 2015 | 0 % | 47.57 % | 51.92 % |
| 2014 | 0 % | 35.31 % | 35.31 % |
| 2013 | 0 % | -133.72 % | -130.23 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2013 | 0 % | -133.72 % | -130.23 % |
| 2014 | 0 % | 35.31 % | 35.31 % |
| 2015 | 0 % | 47.57 % | 51.92 % |
| 2016 | 0 % | -45.26 % | -30.6 % |
| 2017 | 0 % | -110.84 % | -130.05 % |
| 2018 | 0 % | -688.89 % | -708.33 % |
| 2019 | 0 % | 40.27 % | 41.09 % |
| 2020 | 0 % | -398.05 % | -401.95 % |
| 2021 | 0 % | 0 % | 0 % |
| 2022 | 0 % | -1,815.38 % | -1,815.38 % |
| 2023 | 0 % | -362.3 % | -366.41 % |
| 2024e | 0 % | -123.53 % | -136.63 % |
| 2025e | 0 % | -0.96 % | -8.42 % |
| 2026e | 0 % | -44.19 % | -58.35 % |
| 2027e | 0 % | -28.16 % | 8.6 % |
| 2028e | 0 % | -1.82 % | 22.1 % |
| 2029e | 0 % | 73.59 % | 46.87 % |
| 2030e | 0 % | 64.94 % | 56.39 % |
AC Immune Aktienanalyse
What does AC Immune do?
AC Immune SA is a biopharmaceutical company specializing in the discovery and development of drugs for the treatment of neurodegenerative diseases as well as cancer. It was founded in 2003 by a group of leading researchers in the field of neurodegeneration and is based in Lausanne, Switzerland. The company has established itself as one of the leading companies in Alzheimer's research in recent years. AC Immune SA focuses on developing drugs targeting protein aggregation that occurs in Alzheimer's and other neurodegenerative diseases in the brain. It has developed an innovative platform technology that allows for the development of specific antibodies that selectively bind to certain toxic or disease-causing proteins. AC Immune has developed a variety of proprietary technologies and platforms that enable rapid and efficient identification, testing, and optimization of therapeutics. Its main products are antibodies that therapeutically target Alzheimer's, Parkinson's, TAU, and Alpha-Synuclein prions. These antibodies that target protein disease-related plaques help slow disease progression and alleviate symptoms. AC Immune has also developed and tested drugs for cancer treatment. The company operates in two main segments: research and development, as well as clinical studies. It has a strong pipeline of products in development that are in various stages of clinical trials. These products target various diseases including Alzheimer's, Parkinson's, advanced stage cancer, prion diseases, neurodegenerative sanatoria, and Down syndrome. AC Immune SA collaborates closely with various academic research institutions, biotechnology companies, pharmaceutical companies, and government agencies to bring innovative therapies to market. It has formed numerous partnerships and alliances with renowned partners in the pharmaceutical, biotech, and life science industries to accelerate the translation of promising therapeutic approaches into clinical applications. Recently, AC Immune SA announced a partnership with Genentech, a leading company in the development of biological therapies and diagnostic procedures. The two companies are working together to develop treatments for Alzheimer's and several other neurodegenerative diseases. Another example is the collaboration with Eli Lilly and Company for the use of ACI-3024 in the fight against tauopathies, including Alzheimer's disease and progressive supranuclear palsy. AC Immune SA has a strong foundation in scientific research and development, as well as in the commercialization of therapeutics. The company has a comprehensive product pipeline aimed at developing innovative therapy options for patients with neurodegenerative diseases and cancer. With its proprietary technology platform and partnerships with leading companies in the biotech and pharmaceutical industries, AC Immune SA has great potential to make significant advances in the development of therapies that improve patients' lives and enhance their quality of life. AC Immune ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding AC Immune's Sales Figures
The sales figures of AC Immune originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing AC Immune’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize AC Immune's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in AC Immune’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about AC Immune stock
How much was the turnover of the company AC Immune compared to the previous year?
The revenue of AC Immune has increased by 106.05% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of AC Immune?
The revenue of AC Immune is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of AC Immune measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of AC Immune so important for investors?
The revenue of AC Immune is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does AC Immune pay?
Over the past 12 months, AC Immune paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AC Immune is expected to pay a dividend of 0 CHF.
What is the dividend yield of AC Immune?
The current dividend yield of AC Immune is .
When does AC Immune pay dividends?
AC Immune pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of AC Immune?
AC Immune paid dividends every year for the past 0 years.
What is the dividend of AC Immune?
For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.
In which sector is AC Immune located?
AC Immune is assigned to the 'Health' sector.
Wann musste ich die Aktien von AC Immune kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AC Immune from 8/17/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 8/17/2024.
When did AC Immune pay the last dividend?
The last dividend was paid out on 8/17/2024.
What was the dividend of AC Immune in the year 2023?
In the year 2023, AC Immune distributed 0 CHF as dividends.
In which currency does AC Immune pay out the dividend?
The dividends of AC Immune are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von AC Immune
Our stock analysis for AC Immune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AC Immune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
